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OPINION
Fluvoxamine
C Lindsay DeVane
Medical University of South Carolina, Charleston SC, USA
The experience of anxiety at a level that results in
dysfunction appears to be an historical phenomenon
accompanying cultural development. Homer’s fictional
histories describe the streets of Athens as filled with soldiers
bearing the mental, as well as physical, wounds of war.
Obsessions and hand-washing rituals were immortalized by
Shakespeare in the character of Lady Macbeth. Modern
epidemiology has characterized a staggering burden of
anxiety disorders. Fortunately, the last several decades of
psychopharmacology have been a time of major treatment
breakthroughs. The development of the selective serotonin
reuptake inhibitors (SSRIs) has had a profound effect on
the treatment of both depression and anxiety disorders.
These are safe and effective medications with evidence-
based support from randomized controlled trials for their
use across the life span from adolescence to late life.
It is remarkable that a drug first registered for the
treatment of depression, fluvoxamine, should eventually be
proven effective for treatment of all the major DSM-IV
anxiety disorders. Fluvoxamine is well established in the
treatment of obsessive compulsive disorder (OCD) in adults
and children, and shows efficacy in its eastern equivalent
taijin kyofusho. Recent studies also show good efficacy in
social anxiety disorder (SAD) in adults and children. Like
the other SSRIs, there is somewhat less evidence available
for efficacy in panic disorder, but fluvoxamine has significant
advantages over the benzodiazepines in day-to-day usage.
Whilst improvements have been shown in patients with post-
traumatic stress disorder, this illness continues to prove more
refractory to pharmacological intervention than most anxiety
disorders. Fluvoxamine shows efficacy in the group of
illnesses some have characterized as the obsessive-
compulsive spectrum disorders. Such disorders include a
number of eating disorders, pathological gambling, body
dysmorphic disorder, and even compulsive shopping.
Although the methodology of some of the trials is imperfect,
this is a large group of related disorders for which
fluvoxamine may have utility.
Fluvoxamine has a benign safety profile in all age
groups, from children to the very elderly. Fluvoxamine’s
efficacy and benign safety profile in children and adolescents
should reassure prescribers about the use of this SSRI in
young people. This is particularly important since OCD and
SAD  frequently make their first appearance in children and
adolescents, and prescribers need treatments that can be used
effectively and safely in these young patients. Fluvoxamine
is very safe in overdose (even in concomitant overdose with
other drugs) and is associated with a low incidence of
suicidality. When compared with other treatment options
for anxiety disorders, it causes markedly fewer cardio-
vascular, anticholinergic, and cognitive side effects than the
tricyclic antidepressants and it lacks the cognitive
impairment and dependence susceptibility of the benzo-
diazepines. Although it demonstrates a similar overall
tolerability profile to the other SSRIs, causing mainly
gastrointestinal complaints, it has benefits over other
members of this class with respect to sexual side effects,
cognitive and sleep disturbance, change in body weight, and
the appearance of withdrawal syndrome.
Although fluvoxamine should be used with caution in
patients with hepatic impairment and those using drugs
metabolized by cytochrome 1A2 (and to a lesser extent
cytochrome P3A4 and cytochrome P2C19), its use in
patients with renal impairment and in the young and old is
uncomplicated, although gradual titration is to be favored
in very elderly patients.
While a drug’s pharmacokinetics vary across patients,
its pharmacologic actions should remain constant. This fact
underscores the need for support of basic scientific inquiries
into the pharmacology of our most useful medicines. These
investigations can provide insight into the pathophysiology
of psychiatric causes of disability and suggest new molecular
targets for drug development. In this regard, fluvoxamine
and other SSRIs have served as valuable tools to probe the
serotonergic neuronal systems. In conjunction with
functional neuroimaging and pharmacogenetic inquiry, we
can expect further progress in the future to improve the
quality of life of persons susceptible to, experiencing, or
recovering from, mental illness. While we may not fully
understand the reasons why fluvoxamine is such an effective
agent in reducing anxiety, we can be comforted that
substantial evidence, as summarized in the present review,
is available to support its use as contemporary
pharmacotherapy.